MEMichael Eberhardson

Michael Eberhardson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael Eberhardson has a total of 67 co-authors. Here are the top co-authors by number of shared publications:

  • Ola Olén

    Karolinska Institutet, Clinical Epidemiology Unit, Department of Medicine Solna, Stockholm , Sweden

    3 shared publications
  • Anders Ekbom

    Clinical Epidemiology Division Department of Medicine Solna Karolinska Institutet Stockholm Sweden

    2 shared publications
  • Emily Brück

    Department of Physiology and Pharmacology Karolinska Institutet Stockholm Sweden

    2 shared publications
  • Helena Rolandsdotter

    Department of Gastroenterology, Sachs' Children and Youth Hospital, Stockholm, Sweden; Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden

    2 shared publications
  • Peder S. Olofsson

    Laboratory of Immunobiology, Center for Bioelectronic Medicine, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

    2 shared publications
  • Ulrika L. Fagerberg

    Department of Pediatrics, Västmanland hospital, Västerås, Sweden; Center for Clinical Research, Västmanland Hospital Västerås, Region Västmanland - Uppsala University, Sweden; Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden

    2 shared publications

Latest Publications

  • Open Access

    The Risk of Serious Infections Before and After Anti-TNF Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study

    by Johanna Holmgren, Anna Fröborg, Isabella Visuri, Jonas Halfvarson, Henrik Hjortswang, Pontus Karling, Pär Myrelid, Ola Olén, The SWIBREG study group, Malin Olsson, et al.

    Background: Serious infections have been observed in patients with inflammatory bowel disease (IBD) on anti-TNF use—but to what extent these infections are due to anti-TNF or the disease activity per se is hard to disentangle. We aimed to describe how the rates of serious infections change over time both before and after starting anti-TNF in IBD.Methods: Inflammatory bowel disease patients naïve to anti-TNF treatment were identified at 5 centers participating in the Swedish IBD Quality Register, and their medical records examined in detail. Serious infections, defined as infections requiring in-patient care, the year before and after the start of anti-TNF treatment were evaluated.Results: Among 980 patients who started their first anti-TNF therapy between 1999 and 2016, the incidence rate of serious infections was 2.19 (95% CI,1.43-3.36) per 100 person years the year before and 2.11 (95% CI, 1.33-3.34) per 100 person years 1 year after treatment start. This corresponded to an incidence rate ratio 1 year after anti-TNF treatment of 0.97 (95% CI, 0.51-1.84). Compared with before anti-TNF therapy, the incidence of serious infection was significantly decreased more than 1 year after treatment (incidence rate ratio 0.56; 95% CI, 0.33-0.95; P = .03).Conclusions: In routine clinical practice in Sweden, the incidence rate of serious infection among IBD patients did not increase with anti-TNF therapy. Instead, serious infections seemed to decrease more than 1 year after initiation of anti-TNF treatment.


  • Open Access

    Tumour necrosis factor inhibitors in Crohn's disease and the effect on surgery rates

    by Michael Eberhardson, Pär Myrelid, Jonas K. Söderling, Anders Ekbom, the SWIBREG Study Group, Åsa H. Everhov, Charlotte R. H. Hedin, Martin Neovius, Jonas F. Ludvigsson, Ola Olén

    Aim: Surgery is an important therapeutic option for Crohn's disease. The need for first bowel surgery seems to have decreased with the introduction of tumour necrosis factor inhibitors (TNFi; adalimumab or infliximab). However, the impact of TNFi on the need for intestinal surgery in Crohn's disease patients irrespective of prior bowel resection is not known. The aim of this work is to compare the incidence of bowel surgery in Crohn's disease patients who remain on TNFi treatment versus those who discontinue it.Method: We performed a nationwide register‐based observational cohort study in Sweden of all incident and prevalent cases of Crohn's disease who started first‐line TNFi treatment between 2006 and 2017. Patients were categorized according to TNFi treatment retention less than or beyond 1 year. The study cohort was evaluated with regard to incidence of bowel surgery from 12 months after the first ever TNFi dispensation.Results: We identified 5003 Crohn's disease patients with TNFi exposure: 3748 surgery naïve and 1255 with bowel surgery prior to TNFi initiation. Of these patients, 7% (n = 353) were subjected to abdominal surgery during the first 12 months after the start of TNFi and were subsequently excluded from the main analysis. A majority (62%) continued TNFi for 12 months or more. Treatment with TNFi for less than 12 months was associated with a significantly higher surgery rate compared with patients who continued on TNFi for 12 months or more (hazard ratio 1.26, 95% CI 1.09–1.46; p = 0.002).Conclusion: Treatment with TNFi for less than 12 months was associated with a higher risk of bowel surgery in Crohn's disease patients compared with those who continued TNFi for 12 months or more.


  • Open Access

    The brain–gut axis, inflammatory bowel disease and bioelectronic medicine

    by Michael Eberhardson, Yaakov A Levine, Laura Tarnawski, Peder S Olofsson

    The hallmark of inflammatory bowel diseases (IBD) is chronic intestinal inflammation with typical onset in adolescents and young adults. An abundance of neutrophils is seen in the inflammatory lesions, but adaptive immunity is also an important player in the chronicity of the disease. There is an unmet need for new treatment options since modern medicines such as biological therapy with anti-cytokine antibodies still leave a substantial number of patients with persisting disease activity. The role of the central nervous system and its interaction with the gut in the pathophysiology of IBD have been brought to attention both in animal models and in humans after the discovery of the inflammatory reflex. The suggested control of gut immunity by the brain–gut axis represents a novel therapeutic target suitable for bioelectronic intervention. In this review, we discuss the role of the inflammatory reflex in gut inflammation and the recent advances in the treatment of IBD by intervening with the brain–gut axis through bioelectronic devices.


  • Open Access

    Plasma HMGB1 levels and physical performance in ICU survivors

    by Emily Brück, Anna Svensson‐Raskh, Jacob W. Larsson, April S. Caravaca, Alessandro L. Gallina, Michael Eberhardson, Peter V. Sackey, Peder S. Olofsson

    Purpose Physical impairment after critical illness is recognized as a part of the post‐intensive care syndrome (PICS). About one third of intensive care unit (ICU) survivors suffer from long‐term physical disability, yet the underlying pathophysiological mechanisms remains poorly understood. The pro‐inflammatory alarmin, high mobility group box 1 (HMGB1), promotes muscle dysfunction in experimental models, and HMGB1 stays elevated in some patients after ICU discharge. Accordingly, we investigated the relationship between HMGB1 plasma levels and physical performance in ICU survivors. Methods Prospective cohort study of 100 ICU survivors from the general ICU at the Karolinska University Hospital, Sweden. Patients returned for follow up at three (58 patients) and six months (51 patients) after ICU discharge. Blood samples were collected, and a 6‐min walk test (6‐MWT), a handgrip‐strength test (HST), and a timed‐stands test (TST) performed. Results Compared to reference values of the different physical tests, 16% of patients underperformed at all tests at three months and 12% at six months. All test results, except hand‐grip strength left, improved significantly over the follow‐up period (p < 0.05). There was no significant association between plasma HMGB1 levels at three and six months and scores on the three tests (6‐MWT, TST, HST) (p = 0.50 ‐ 0.69). Conclusion In this follow‐up study of ICU survivors, we found no significant association between plasma HMGB1 levels and physical performance. Additional follow‐up studies of HMGB1 plasma levels and muscle function in ICU survivors are still warranted.


  • Open Access

    Vagotomy and subsequent risk of inflammatory bowel disease: a nationwide register‐based matched cohort study

    by Bojing Liu, Alkwin Wanders, Karin Wirdefeldt, Arvid Sjölander, Michael C. Sachs, Michael Eberhardson, Weimin Ye, Anders Ekbom, Ola Olén, Jonas F. Ludvigsson

    Summary: Background: The vagus nerve provides essential parasympathetic innervation to the gastrointestinal system and is known to have anti‐inflammatory properties.Aims: To explore the relationship between vagotomy and the risk of inflammatory bowel disease (IBD) and its major categories: Crohn's disease (CD) and ulcerative colitis (UC).Methods: A matched cohort comprising 15 637 patients undergoing vagotomy was identified through the Swedish Patient Register from 1964 to 2010. Each vagotomised patient was matched for birth year and gender with 40 nonvagotomised individuals on the date of vagotomy. We estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for IBD using flexible parametric models adjusted for matching variables, year of vagotomy, birth country, chronic obstructive pulmonary disease and comorbidity index.Results: We observed 119 (0.8%) patients with vagotomy developed IBD compared to 3377 (0.5%) IBD cases in nonvagotomised individuals. The crude incidence of IBD (per 1000 person‐years) was 0.38 for vagotomised patients and 0.25 for nonvagotomised individuals. We observed a time‐dependent elevated risk of IBD associated with vagotomy, for instance, the HR (95% CI) was 1.80 (1.40‐2.31) at year 5 and 1.49 (1.14‐1.96) at year 10 post‐vagotomy. The association appeared to be stronger for truncal than selective vagotomy and limited to CD (HR was 3.63 [1.94‐6.80] for truncal and 2.06 [1.49‐2.84] for selective vagotomy) but not UC (1.36 [0.71‐2.62] for truncal and 1.25 [0.95‐1.63] for selective vagotomy).Conclusions: We found a positive association between vagotomy and later IBD, particularly for CD. The finding indirectly underlines the beneficial role of the vagal tone in IBD.


  • Open Access

    Lack of clinically relevant correlation between subjective and objective cognitive function in ICU survivors: a prospective 12-month follow-up study

    by Emily Brück, Jacob W. Larsson, Julie Lasselin, Matteo Bottai, Tatja Hirvikoski, Eva Sundman, Michael Eberhardson, Peter Sackey, Peder S. Olofsson

    Cognitive impairment and psychological distress are common in intensive care unit (ICU) survivors. Early identification of affected individuals is important, so intervention and treatment can be utilized at an early stage. Cognitive Failures Questionnaire (CFQ) is commonly used to screen for subjective cognitive function, but it is unclear whether CFQ scores correlate to objective cognitive function in this population. Between 2014 and 2018, 100 ICU survivors aged 18–70 years from the general ICU at the Karolinska University Hospital, Solna, were included in the study. Out of these, 58 patients completed follow-up at 3 months after ICU discharge, 51 at 6 months, and 45 at 12 months. Follow-up included objective cognitive function testing using the Cambridge Neuropsychological Test Automated Battery (CANTAB) and subjective cognitive function testing with the self-rating Cognitive Failures Questionnaire (CFQ), as well as psychological self-rating with the Post-Traumatic Stress Symptoms Scale-10 (PTSS-10) and Hospital Anxiety and Depression Scale (HADS). The prevalence of cognitive impairment as measured by four selected CANTAB tests was 34% at 3 months after discharge, 18% at 6 months, and 16% at 12 months. There was a lack of significant correlation between CANTAB scores and CFQ scores at 3 months (r = − 0.134–0.207, p > 0.05), at 6 months (r = − 0.106–0.257, p > 0.05), and at 12 months after discharge (r = − 0.070–0.109, p > 0.05). Correlations between CFQ and PTSS-10 scores and HADS scores, respectively, were significant over the follow-up period (r = 0.372–0.710, p ≤ 0.001–0.023). In contrast, CANTAB test scores showed a weak correlation with PTSS-10 and HADS scores, respectively, at 3 months only (r = − 0.319–0.348, p = 0.008–0.015). We found no clinically relevant correlation between subjective and objective cognitive function in this cohort of ICU survivors, while subjective cognitive function correlated significantly with psychological symptoms throughout the follow-up period. Treatment and evaluation of ICU survivors’ recovery need to consider both subjective and objective aspects of cognitive impairment, and subjective reports must be interpreted with caution as an indicator of objective cognitive function.


  • Open Access

    Exclusive Enteral Nutrition: Clinical Effects and Changes in Mucosal Cytokine Profile in Pediatric New Inflammatory Bowel Disease

    by Helena Rolandsdotter, Kerstin Jönsson-Videsäter, Ulrika L. Fagerberg, Yigael Finkel, Michael Eberhardson

    Exclusive Enteral Nutrition (EEN) is the first-line treatment in children with Crohn’s disease (CD) for induction of remission. However, the mode of action remains conjectural. The aim of this study was to investigate whether the effect of EEN is paralleled by changes in the mucosal cytokine profiles (MCP). Twelve children with new onset inflammatory bowel disease (IBD) received induction treatment with a polymeric EEN. We assessed clinical, endoscopic and histologic scoring before and after EEN. Twelve colonic cytokines were analyzed by Polymerase Chain Reaction (PCR) in six of the IBD patients at onset and after EEN as well as in six non-IBD control children at the diagnostic colonoscopy. Twelve children completed 6 weeks of EEN, except from one child who completed 4 weeks. At the control colonoscopy, 83% were in complete clinical remission. Changes were found in the MCPs of individual patients after EEN. In particular, children with IBD showed significantly higher values of Interleukin (IL)-12β (p = 0.008) and IL-23α (p = 0.02) compared to non-IBD controls at the diagnostic colonoscopy. Furthermore, an overall change in proinflammatory cytokines was noted in the IBD-group after treatment. Further studies are warranted to understand the role of EEN in MCP.


  • Open Access

    Towards improved control of inflammatory bowel disease

    by Michael Eberhardson, Charlotte R. H. Hedin, Marie Carlson, Laura Tarnawski, Yaakov A. Levine, Peder S. Olofsson

    Inflammatory bowel disease (IBD) is characterized by activation of both the innate and adaptive immune system in genetically susceptible individuals, resulting in chronic intestinal inflammation. The triggers that initiate and perpetuate this continuous inflammation are the subject of much speculation and research, although the central role of the intestinal microbiota is recognized, and is even a target for treatment in some circumstances. The mainstay of modern IBD treatment is suppression of the immune response towards as yet unspecified antigens, and conventional therapy includes corticosteroids, 5‐aminosalicylic acid (5‐ASA), thiopurines and methotrexate. Reducing activity of specific mediators has proven efficacious, including adhesion molecules, such as the gut‐homing integrin α4β7 expressed on the surface of circulating immune cells, and cytokines, such as tumour necrosis factor α (TNF‐α). This has been achieved using biologic agents including monoclonal antibodies. Recent discoveries in immunology and neuroscience have revealed that signals in the peripheral nervous system regulate inflammation, including levels of TNF‐α. The understanding of the mechanisms of the neuro‐immune communication involved in inflammation control in the gut is evolving, but is as yet incomplete. Clinical studies using implanted vagus nerve stimulators for treatment of IBD show encouraging results. Accordingly, the neural reflex control of inflammation is emerging as a potential therapeutic target in treatment of IBD. Here, we review current therapeutic options and neural reflex control of gut immunity in the context of intestinal inflammation.


  • Open Access

    Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on  Maintenance Treatment

    by Helena Rolandsdotter, Per Marits, Ulf Sundin, Ann-Charlotte Wikström, Ulrika L. Fagerberg, Yigael Finkel, Michael Eberhardson

    The role of trough serum infliximab (s-IFX) and antibodies toward IFX (ATI) during maintenance treatment remains unclear in children. The aim of the present study was to investigate trough s-IFX and ATI to identify any correlation with inflammatory activity and clinical response in a pediatric inflammatory bowel disease (IBD) cohort. We investigated the s-IFX trough levels in pediatric IBD patients (n = 45) on maintenance IFX treatment. Ninety-three blood samples were collected and demographics, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and albumin were recorded. The mean s-IFX trough level was 5.2 µg/mL. The mean trough s-IFX level was significantly higher in the samples taken during remission (7.2 µg/mL) compared to active disease (4.5 µg/mL, p < 0.05). The trough s-IFX levels correlated with ESR, CRP, and albumin. S-IFX was undetectable in eight of the patients, all with positive ATI and active disease. Surprisingly, clinical and biochemical remission was observed at only 26 of the 93 visits. The correlation between dose variations and changes in trough s-IFX was not evident. In line with studies in adults, the s-IFX trough levels correlated with response to infliximab.